Screener / SEC EDGAR /CIK 0000856982 /10-K filed Feb 24, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Medical Instruments

Merit Medical Systems Inc MMSI

Merit Medical Systems, Inc. is a leading manufacturer and marketer of proprietary medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. 10-K, Item 1

Employees
7,500
Headquarters
South Jordan, UT
Next results
around Jan 7, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $1.5B through the costs to a net profit of $128.5M · income statement of the 10-K

12% operating margin
Revenue to Gross profit: $738.3MRevenue to Cost of revenue: $777.6MGross profit to Operating profit: $184.7MGross profit to Operating expenses: $553.5MOperating profit to Net profit: $128.5MOperating profit to Tax & other: $56.2MOperating expenses to R&D: $97.4MOperating expenses to SG&A: $456.2M Revenue: $1.5B REVENUE $1.5B +12% Y/Y Gross profit: $738.3M · 49% margin GROSS PROFIT $738.3M 49% margin · +15% Y/Y Cost of revenue: $777.6M · 51% of revenue COST OF REVENUE $777.6M 51% of revenue Operating profit: $184.7M · 12% margin OPERATING PROFIT $184.7M 12% margin · +19% Y/Y Operating expenses: $553.5M · 37% of revenue OPERATING EXPENSES $553.5M 37% of revenue Net profit: $128.5M · 8% margin NET PROFIT $128.5M 8% margin · +7% Y/Y Tax & other: $56.2M · 4% of revenue TAX & OTHER $56.2M 4% of revenue R&D: $97.4M · 6% of revenue R&D $97.4M 6% of revenue SG&A: $456.2M · 30% of revenue SG&A $456.2M 30% of revenue
Gross profit $738.3M 49% margin · +15% Y/Y
Operating profit $184.7M 12% margin · +19% Y/Y
Net profit $128.5M 8% margin · +7% Y/Y
The full income statement, year by year

MMSI among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 11.8%, above 55% of 154 peers (their median 10.4%) REVENUE GROWTH 11.8% · above 55% Gross margin: 49.4%, above 26% of 107 peers (their median 63.8%) GROSS MARGIN 49.4% · above 26% Operating margin: 13.5%, above 64% of 138 peers (their median 9.8%) OPERATING MARGIN 13.5% · above 64% Net margin: 9.9%, above 59% of 153 peers (their median 6.7%) NET MARGIN 9.9% · above 59% FCF margin: 12.6%, above 57% of 144 peers (their median 9.9%) FCF MARGIN 12.6% · above 57% Return on capital: 5.6%, above 22% of 89 peers (their median 9.2%) RETURN ON CAPITAL 5.6% · above 22%
MMSI Peer median Below the median

What changed

12 new risk paragraphs. 10-K filed Feb 24, 2026 against Feb 25, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 11 checks found nothing to note

  • Receivables +7.1% ($190.2M to $203.7M) vs revenue +11.8% ($1.4B to $1.5B), -4.7 pts apart
  • Cash from operations $297.4M vs net income $128.5M (FY ending Dec 31, 2025)
  • Inventory +9.0% ($306.1M to $333.7M) vs revenue +11.8% ($1.4B to $1.5B), -2.7 pts apart
8 more checks with nothing to note
  • Same auditor in both 10-Ks: DELOITTE & TOUCHE LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Inventories - Provision for estimated excess, slow moving and obsolete inventories; Intangible Assets - Biolife Developed Technology
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

12 paragraphs in Risk Factors that were not in the 10-K filed Feb 25, 2025. Quoted as filed.

All 12 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    Furthermore, tariffs or other trade restrictions may lead to continuing uncertainty and volatility in U.S. and global financial and economic conditions and commodity markets, significant inflation, and reduced demand for our products. Also, disruptions and volatility in the financial markets may lead to adverse changes in the…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    Furthermore, we may find limited demand for otherwise promising new products unless reimbursement approval is obtained from private and governmental third-party payers. Legislative or administrative reforms to the reimbursement systems in the U.S., Japan, China, or other countries in a manner that significantly reduces or eliminates…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    The development, deployment and use of AI in our business operations could result in regulatory action, legal liability, operational challenges or reputational harm and our failure to adapt to developments related to AI in a timely manner (or at all) could adversely affect our business, financial condition or results of operations. We…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    Effective October 3, 2025, Fred Lampropoulos resigned as Chief Executive Officer and President of Merit and Merit’s Board of Directors appointed Martha G. Aronson as a Director and as Merit’s new Chief Executive Officer and President. Additionally, effective January 4, 2026, Mr. Lampropoulos resigned as a Director and Chair of the Board…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$1.2B$1.3B$1.4B$1.5B
Net income$74.5M$94.4M$120.4M$128.5M
Operating cash flow$114.3M$145.2M$220.8M$297.4M
Free cash flow$69.3M$110.9M$185.7M$215.7M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$1.5B ▲ 11.8% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

4 filings in the last 30 days · SEC EDGAR

All filings

About the company

Merit Medical Systems Inc, South Jordan, UT · from the 10-K filed Feb 24, 2026

Merit Medical Systems, Inc. is a leading manufacturer and marketer of proprietary medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. We strive to be the most customer-focused company in healthcare. Each day we are determined to make a difference by understanding our customers’ needs and innovating and delivering a diverse range of products that improve the lives of people and communities throughout the world.

Headquarters
South Jordan, UT
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Oct 29, 2026
Incorporated in
UT

Employees, at the top of the page: "As of December 31, 2025, we had approximately 7,500 employees located in approximately 43 countries performing a variety of roles" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 24, 2026 (open at SEC), compared with the 10-K filed Feb 25, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MMSI/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.